[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lrrk2\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lrrk2":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100645363","lrrk2-parkinsons-disease-fingerprint-100645363",false,"NCT07681219","LRRK2 Parkinson's Disease Fingerprint","LRRK2 Associated Parkinson's Disease: Definition of a Clinical, Molecular and Neurophysiological Fingerprint","NEU-PD","Inclusion Criteria:\n\n* age 30-80 years,\n* clinically established diagnosis of PD according to the Movement Disorders Society (MDS) diagnostic criteria,\n* Hoehn \\& Yahr (H\\&Y) stage between 1 and 3,\n* 10 patients with a LRRK2 associated parkinsonism and 10 with sporadic PD tested with a NGS panel and MLPA for PD associated genes,\n* ability to provide informed consent.\n\nExclusion Criteria:\n\n* Active or history of other neurological disorders,\n* active infectious disease or history within the previous 4 weeks,\n* continuative therapy (at least 1 week) with NSAIDs or steroids within the previous 12 weeks,\n* active malignancy, autoinflammatory or autoimmune diseases or history within the previous 3 years;\n* alcohol or drug abuse or dependence\n* any contraindication to the execution of the MRI (including claustrophobia).","ALL","30 Years","80 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this interventional monocentric study is to identify molecular and clinical markers of LRRK2-related Parkinson's disease through blood markers analysis and deep clinical phenotyping. Patients who meet the inclusion criteria, after signing the informed consent form will be clinically evaluated by a neurologist expert in movement disorders. Eventually, patients will undergo a blood sample collection, a brain MRI, and a high density EEG. All data will be collected using an ad hoc electronic Case Report Form (CRF) developed for the study",[28,29],"Parkinsons Disease (PD)","LRRK2","NOT_YET_RECRUITING","2026-06-26",{"date":33,"type":34},"2026-07-02","ACTUAL",{"date":36,"type":22},"2026-09-01",{"date":38,"type":22},"2029-09-01",{"name":40,"class":41},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER"]